Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Lida, Mina"'
Autor:
Jessica D. Austin, Emily James, Rachel L Perez, Gina L. Mazza, Juliana M. Kling, Jessica Fraker, Lida Mina, Imon Banerjee, Richard Sharpe, Bhavika K. Patel
Publikováno v:
BMC Women's Health, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Breast imaging clinics in the United States (U.S.) are increasingly implementing breast cancer risk assessment (BCRA) to align with evolving guideline recommendations but with limited uptake of risk-reduction care. Effectively com
Externí odkaz:
https://doaj.org/article/12a763faecf44bb081a924bb6ea10e39
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 22, p 16198 (2023)
Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer. However, advanced tumors develop resistance to endocrine therapy, rendering it ineffective as the disease progresses. There are several molecular mechanisms of
Externí odkaz:
https://doaj.org/article/36af0333fe38426aa82142cea76ea66f
Autor:
Zev A. Wainberg, Lauren Averett Byers, Nicola J. Curtin, Miranda Patterson, Ashleigh Herriott, Joshua W. Henshaw, David C. Smith, John Heymach, Jasgit Sachdev, Stan Kaye, Saeed Rafii, John Glaspy, Rashmi Chugh, Lida Mina, Ramesh K. Ramanathan, Johann de Bono
Supplementary Figure S1. Talazoparib inhibition of PBMC PARP activity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e95db2be5b81e9a0f3ad86b8281bd1
https://doi.org/10.1158/2159-8290.22531110
https://doi.org/10.1158/2159-8290.22531110
Autor:
Zev A. Wainberg, Lauren Averett Byers, Nicola J. Curtin, Miranda Patterson, Ashleigh Herriott, Joshua W. Henshaw, David C. Smith, John Heymach, Jasgit Sachdev, Stan Kaye, Saeed Rafii, John Glaspy, Rashmi Chugh, Lida Mina, Ramesh K. Ramanathan, Johann de Bono
Supplementary Methods includes additional details on these topics: tumors eligible for dose escalation phase; tumors eligible for dose expansion phase; patients enrolled using a local laboratory; study design and participants; additional inclusion cr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c35bb32f493e71bbc643b22bb0b3649
https://doi.org/10.1158/2159-8290.22531107.v1
https://doi.org/10.1158/2159-8290.22531107.v1
Autor:
Zev A. Wainberg, Lauren Averett Byers, Nicola J. Curtin, Miranda Patterson, Ashleigh Herriott, Joshua W. Henshaw, David C. Smith, John Heymach, Jasgit Sachdev, Stan Kaye, Saeed Rafii, John Glaspy, Rashmi Chugh, Lida Mina, Ramesh K. Ramanathan, Johann de Bono
Supplementary Table S1. Dose-response and exposure-response parameters.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b99fccdd412f6f65d1dfdcba0f9d8d0
https://doi.org/10.1158/2159-8290.22531104
https://doi.org/10.1158/2159-8290.22531104
Autor:
Judy S. Wang, Muralidhar Beeram, Pavani Chalasani, Lida Mina, Rebecca A. Shatsky, Sara Hurvitz, Meghna S. Trivedi, Robert Wesolowski, Hyo S. Han, Amita Patnaik, Shakeela Bahadur, My-my Huynh, Aarthi Jayanthan, Gerrit Los, Sandra E. Dunn, Andrew Dorr
Publikováno v:
Cancer Research. 83:P4-01
Background: Breast cancer (BC) is the most common malignancy in women and metastatic triple negative breast cancer (mTNBC) remains one of the most difficult to treat cancers with few targeted treatment options. RSK is recognized as a critical signali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86f4a4955f1917d426df057f63a82306
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-16
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-16
Publikováno v:
Cancer Research. 81:PS7-20
Introduction Approximately one out of eight women are diagnosed with breast cancer in their lifetime. Women are recommended to begin annual mammograms at age 40 unless they are high-risk risk for breast cancer based on risk algorithms or positive ger
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96ceab050ce044fe878701c672731655
https://doi.org/10.1158/1538-7445.sabcs20-ps7-20
https://doi.org/10.1158/1538-7445.sabcs20-ps7-20
Publikováno v:
Cancers. 14(17)
Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors (PARPi) are approved for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e65659bf9696490e7dffb3fa8750be96
https://pubmed.ncbi.nlm.nih.gov/36077867
https://pubmed.ncbi.nlm.nih.gov/36077867
Publikováno v:
Clinical Oncology and Research. :1-4
Use of adjuvant endocrine therapy for women with hormone-receptor (HR)-positive breast cancer has become the standard of care. Tamoxifen, an orally available selective estrogen receptor modulator (SERM), is a commonly used endocrine therapy agent cur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a545f6ae8316edb5ac816f128cd2b43
https://doi.org/10.31487/j.cor.2020.04.11
https://doi.org/10.31487/j.cor.2020.04.11
Autor:
Kevin L. Rand, Bryan P. Schneider, Adam T. Hirsh, Catherine E. Mosher, Kathy D. Miller, Lida Mina, Shelley A. Johns, Erin V. Newton, Danielle Tometich, Samantha D. Outcalt, Marianne S. Matthias, Anna Maria Storniolo
Publikováno v:
Supportive Care in Cancer. 26:3781-3788
PURPOSE: Little research has examined cancer patients’ expectations, goals, and priorities for symptom improvement. Thus, we examined these outcomes in metastatic breast cancer patients to provide patients’ perspectives on clinically meaningful s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a93ad2b31429ad2458eb595f20675f3
https://doi.org/10.1007/s00520-018-4244-8
https://doi.org/10.1007/s00520-018-4244-8